Background: Severe anaemia is a major cause of morbidity and mortality in HIV-infected adults living in resource-limited countries. Comprehensive data on the aetiology is lacking and needed to improve outcomes.
Introduction
Anaemia is recognized as the most common haematological complication of Human Immunodeficiency Virus (HIV) infection worldwide (1, 2). The World Health Organization (WHO) defines anaemia as a haemoglobin level below 110-120 g/l. In sub-Saharan Africa, 60% of HIV-infected adults are anaemic and 22% are severely anaemic (3, 4) . Anaemia is independently associated with an increased one-year mortality in HIV infection of 8%, which rises to 55% in those with severe anaemia (5, 6).
To prevent and treat severe anaemia in HIV-infected patients, a comprehensive understanding of the aetiology and pathophysiology is essential. Severe anaemia in HIV infection has been associated with micronutrient deficiencies, infections (viral, bacterial and parasitic), medication induced (zidovudine and co-trimoxazole) and neoplastic diseases (7-11). Only a few studies have comprehensively studied the multifactorial aetiology and pathophysiology of HIV-associated severe anaemia in sub-Saharan Africa despite the high burden of HIV infection in this region (2). Commonly, studies only report on the association between HIV infection and a single cause of severe anaemia, for example iron deficiency, without considering the multiple causes of severe anaemia that may impact on an HIV-infected patient (12, 13). As a consequence, evidence to inform preventive or treatment guidelines for severe anaemia in HIV-infected patients in sub-Saharan Africa is scarce. In practice, severe anaemia management in HIV-infected patients is often still based on the same strategies used for non-HIV infected patients, including iron supplementation, malaria treatment and de-worming (2, 14) . This strategy may be ineffective as the causes of HIV-associated severe anaemia may be different, and even harmful considering that (blind) iron supplementation may exacerbate infections and thus may deteriorate the patients condition (15, 16) .
Better knowledge about the aetiology of severe anaemia is essential in order to develop evidence-based protocols and ultimately improve outcomes for HIV-infected adults with severe anaemia in sub-Saharan Africa. To address this knowledge gap, we performed a comprehensive observational cohort study to explore the prevalence of potential aetiologies of HIV-associated severe anaemia in Malawian in-patients and studied associations between these and the severity of the anaemia and patient outcomes.
Methods
An observational cohort study of HIV-infected patients with severe anaemia (haemoglobin ≤70 g/l) admitted to the Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi between February 2010 and March 2011 was performed. All HIV-infected patients above 18 years of age with severe anaemia admitted to the general medical ward were approached and enrolled in the study if they provided informed consent. A case record form including a detailed medical history and physical examination was completed for each enrolled patient. On admission a venous blood sample was collected and a chest Xray was performed. The patients were managed according to the hospital protocols, which included a blood transfusion if required, treatment of correctable conditions including anti-malarial medication and antibiotics. Antiretroviral treatment (ART) was provided according to the national Malawi guidelines, which stipulated that ARTs should only be initiated by specialist outpatient clinicians, so patients were not initiated on inpatient wards. At the time of the study first line ART was a combination of Stavudine, Lamivudine and Nevirapine and second line treatment was a combination of Zidovudine, Lamivudine, Tenofovir and Lopinavir/Ritonavir (17). ART was only prescribed for WHO stage 3 and 4 disease, or WHO stage 1 and 2 disease with CD4 count < 350 x 10 9 /l (18). Cotrimoxazole was prescribed routinely to all HIV-infected patients on ART as Pneumocystis Jirovecii prophylaxis. For this study patients were followed up in the dedicated ART clinic after discharge. A community research nurse followed those who failed to attend their appointments up at home. Follow-up was done for a maximum of 365 days after enrolment when they attended the ART clinic for routine appointments or, if they failed to attend, by a home visit from a study nurse.
Laboratory assays
All samples were analysed within 24 hours of collection or stored at -80 0 C for further analysis. On enrolment haemoglobin concentrations were measured on the ward using internationally accepted cut-offs were used to define deficiencies (22). Thick blood films were prepared and stained for malaria microscopy. Malaria was defined as the presence of Plasmodium falciparum asexual parasites in the blood films. HIV infection was confirmed using two point-of-care antibody tests (Unigold® and Determine®). A venous blood sample was inoculated into BACTEC Myco/F-Lytic culture vials and incubated in a BACTEC 9050 automated culture system (Becton Dickinson) for 56 days. Sub-culturing blood and sputum, susceptibility testing and isolate identification were performed by standard techniques(23). Possible contaminants were recorded as absence of pathogens.
Sputum cultures were examined for mycobacteria using Ziehl-Nielsen staining. Wholeblood isolates were assessed for Epstein-Barr virus and cytomegalovirus infection by semi-quantitative PCR and for parvovirus B19 by real-time PCR (24). All chest X-rays were reviewed by a radiologist for signs of pulmonary tuberculosis (TB). `When TB was suspected, standardized treatment was started according to the local protocols.
Bone marrow
If the patient's clinical condition allowed and they provided consent, a bone marrow aspirate and trephine biopsy was performed. All bone marrow samples were taken from the posterior iliac crest. Samples of the aspirates were spread onto slides and trephine biopsies were fixed, decalcified and embedded in paraffin wax (25, 26). Bone marrow samples were sent to the Haematopathology Referral Centre at the Royal Liverpool University Hospital, Liverpool UK, for analysis. Sections of the trephine blocks were stained with haematoxylin and eosin and Giemsa, and also for iron with Perls stain, and for reticulin (25). All slides were examined for using a predefined format and diagnoses were allocated to the categories lymphoproliferative disease, myeloproliferative disease, myelodysplastic syndrome (MDS) and TB (27-29). The need for additional histochemical (e.g. Ziehl-Neelsen) or immunohistological (e.g. CD3, CD20) staining was determined according to the local protocol in Liverpool depending on the preliminary morphological findings.
Definitions for potential factors involved in the aetiology of severe anaemia
The following potential factors involved in the aetiology of severe anaemia were defined and evaluated; 1) Unsuppressed HIV-infection; viral load ≥1000 copies/ml. 2)TB: one or more of the following were present: a) positive sputum culture, b) chest X-ray with signs of pulmonary TB and/or c) on going TB treatment at time of enrolment d) clinical diagnosis by local doctor including unknown generalized lymphadenopathy and/or night sweats of > 30 days and of unknown origin e) caseating granulomata in the bone marrow trephine. 3) Malaria: presence of malaria parasites in a thick blood film. 4) Parvovirus B19: viral load of >1000 copies/ml. 5) Cytomegalovirus (CMV); load of >100 copies/ml. 6) Epstein-Barr virus (EBV); viral load >100 copies/ml. 7) Bacteraemia; a blood culture growing a potential pathogen. 8) Underweight (BMI ≤18.5). 9) Serum folate deficiency (≤3 ng/l). 10) Vitamin B12 deficiency (≤180 pg/ml). 11). Iron deficiency was defined as MCV≤ 83 fl (3, 22, 
Results
In total, 199 patients were included in the study: 64.8% were female. The median age was 32 years (IQR 27-61 years). The median haemoglobin was 53 g/l (IQR 4.2-6.3) and 84 (42%) patients had very severe anaemia (hb≤50 g/l 1 Pancytopenia is defined as thrombocytopenia (≤150x10 9 /l) and leukopenia (≤4x10 9 /l) and severe anaemia (≤ 70 g/l) (22). Abbreviations: Hb: Haemoglobin, ART: antiretroviral therapy.
The prevalence of factors that were associated with severe anaemia, and factors that were co-existing in individual patients, are shown in table 2. Overall, patients had a mean of 3 (range 1-8) co-existing aetiologies of severe anaemia (figure 1). Comparing the different risk factors for very severe anaemia (Hb<50g/L) as compared to severe anaemia, EBV/CMV co-infection (OR 2.8 95% CI 1.1-6.9) was the only factor associated with very severe anaemia (table 2) .
During the one-year follow-up period, 101 study patients (50.8%) died. The median time to death was 16 days (IQR 5-41) and 81 (80.1%) of these deaths occurred within 60 days of admission (figure 2). Folate deficiency and end stage renal disease were associated with mortality with Hazard Ratio 2.2 (95% CI 1.2-3.8) and Hazard Ratio 3.2 (95% CI 1.6-6.2) respectively (figure 3).
Neither very severe anaemia (haemoglobin ≤50 g/l), nor the haemoglobin levels were associated with mortality in the study patients (Hazard Ratio 0.9, 95%CI 0.6-1.4 and Hazard Ratio 1.01, 95% CI 0.9-1.2 respectively). 6 Explanatory variables associated with the outcome variables (P > 0.10) in the univariable analysis were excluded in the multivariable model in a stepwise 7 approach (-). Abbreviation: GFR; Glomerular filtration rate.
8 Discussion
9
In this study we described the prevalence of several potential aetiologies for 10 severe and very severe anaemia in HIV-infected Malawian adults. Patients had a mean of 11 three co-existing aetiologies potentially contributing to their anaemia, the most common 12 one being unsuppressed HIV. Mortality in the study patients was extremely high, as 51%
13 of the patients died within one year and most died within 60 days of admission. Severe 14 anaemia in HIV-infected patients in a resource limited setting, such as Malawi, should 15 therefore be treated as a multi-causal critical condition with high mortality.
16
Anaemia is an independent predictor of mortality and disease progression in HIV-17 infected patients and mortality increases with decreasing haemoglobin concentration (6, 18 32). Previous studies reported an estimated one-year mortality of 3.7% in HIV-infected 19 patients without anaemia and up to 30-55% in severe anaemia in resource limited settings 20 (5, 6). Our study results are consistent with these outcomes. Additionally we found that a 21 mean of three contemporaneous aetiologies potentially contributed to severe anaemia in 22 HIV-infected patients. This is important as it highlights the multi-causality of severe 23 anaemia in this population. Clinicians should therefore not just focus on a single cause 24 and single treatment for severe anaemia in HIV-infected patients. Different treatment 25 protocols from those used traditionally to treat anaemia (e.g. iron and folate) will be 26 needed to address these multiple co-existing aetiologies to enhance improvement of 27 mortality amongst these patients. Also, the seriousness of severe anaemia in HIV-infected 28 patients needs to be better recognized. Currently severe anaemia in HIV-infected patients 29 is classified as a stage 3 clinical condition (33). However due to the high mortality found in 30 our, and previous, studies, we recommend re-classifying severe anaemia as a marker of 31 HIV stage 4 disease.
32
Unsuppressed HIV virus was present in 79% of the patients in our study 33 population. HIV may cause anaemia directly through an inhibitory effect of the HIV-virus 34 on the erythropoietin progenitor cells in the bone marrow, or indirectly through 35 opportunistic infections causing anaemia (34). Although this potential direct/indirect risk 36 factor was very common it was not associated with the severity of the anaemia or 37 mortality in our population, explored in our multivariate analysis. This is in contrast with a 38 large cross-sectional study in Tanzania showed that the risk of developing severe anaemia 39 in HIV-infected patients increased two to three times among patients with advanced HIV 40 disease (3). We therefor postulate that controlling HIV infection by starting or switching 41 ART treatment should therefore be considered as the most important and urgent step in 42 treatment protocols for severely anaemic HIV-infected patients. After our study had been 43 completed guidelines for initiating ART changed. At the time of the study the trigger for 80 in causing anaemia, especially in HIV patients in sub-Saharan Africa (2, 14), is limited and 81 likely to have been overestimated (40, 45).
82
Malnutrition was common in our population as half of the patients' had a BMI 83 below 18.5m 2 and deficiencies of iron and folate were diagnosed in 33.9% and 12% of the 84 patients respectively. The prevalence of iron deficiency in our study is higher than in 85 previous studies on HIV-infected patients in sub-Saharan Africa populations that report 86 prevalence rates of iron deficiency of 18%-25% of anaemic HIV-infected patients (46, 47).
87 Interestingly, adults in sub-Saharan Africa with severe anaemia but without HIV infection, 88 have a higher prevalence of iron deficiency (59%) (45). Data from children with severe 89 anaemia in Malawi also showed a much higher overall prevalence of iron deficiency (47%) 90 than the adults in our study (40 
119
Our study has several limitations. We purposely did not explore factors potentially 120 associated with anaemia that previous studies had shown were uncommon in Malawi,
121
such as haemoglobinopathies and parasitic infections (40, 57). We also did not include an
122
HIV-infected population without severe anaemia against which to compare the 123 prevalence of anaemia aetiologies and clinical outcomes. Only a sub-population of our 124 patients gave consent for bone marrow sampling. Although these were an unselected 125 group of patients it is possible that this may have introduced a hidden bias, for example 126 by excluding the patients who were particularly unwell. Nevertheless, our findings are 127 very valuable since bone marrow data from HIV-infected African patients is very scarce.
129
Conclusion
130
Our study has demonstrated that severe anaemia in HIV-infected adults in Malawi is 131 associated with multiple co-existing aetiologies and has a strikingly high mortality rate.
132
Severe anaemia in HIV-infected patients is therefore a critical indicator of mortality and 
